Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matilde Inglese

Showing results (141-150 of 315) with videos related to

Pageof 32
Sort By:
Multiple Sclerosis and Related Disorders|August 24, 2025
The early effect of induction versus continuous therapies in active multiple sclerosis: a multimodal study on the first course of cladribine versus fingolimodTommaso Sirito, Emilio Cipriano, Caterina Lapucci, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 11, 2017
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MSGiulia Bommarito, Alessandro Bellini, Matteo Pardini, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 31, 2025
Cognitive changes in patients with relapse-free MS treated with high efficacy therapies: the predictive value of paramagnetic rim lesionsVincenzo Daniele Boccia, Elisa Leveraro, Emilio Cipriano, et al.
Journal of Neurology|July 15, 2025
Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysisBruno Kusznir Vitturi, Maria Cellerino, Daniele Boccia, et al.
Journal of Neurology|May 24, 2022
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
European Journal of Neurology|October 28, 2025
Childhood and Adolescent Environmental Risk Factors for Multiple Sclerosis: A Systematic Review With Meta-AnalysisBruno Kusznir Vitturi, Maria Cellerino, Daniele Boccia, et al.
Journal of Neurology|September 22, 2022
Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 18, 2018
Brain microstructural injury occurs in patients with RRMS despite 'no evidence of disease activity'Asaff Harel, Dylan Sperling, Maria Petracca, et al.
Scientific Reports|September 25, 2020
Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deteriorationMario Amatruda, Maria Petracca, Maureen Wentling, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 28, 2019
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MSMaria Cellerino, Christian Cordano, Giacomo Boffa, et al.
Pageof 32

Showing results (141-150 of 315) with videos related to

Sort By:
Pageof 32
Multiple Sclerosis and Related Disorders|August 24, 2025
The early effect of induction versus continuous therapies in active multiple sclerosis: a multimodal study on the first course of cladribine versus fingolimodTommaso Sirito, Emilio Cipriano, Caterina Lapucci, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 11, 2017
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MSGiulia Bommarito, Alessandro Bellini, Matteo Pardini, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 31, 2025
Cognitive changes in patients with relapse-free MS treated with high efficacy therapies: the predictive value of paramagnetic rim lesionsVincenzo Daniele Boccia, Elisa Leveraro, Emilio Cipriano, et al.
Journal of Neurology|July 15, 2025
Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysisBruno Kusznir Vitturi, Maria Cellerino, Daniele Boccia, et al.
Journal of Neurology|May 24, 2022
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
European Journal of Neurology|October 28, 2025
Childhood and Adolescent Environmental Risk Factors for Multiple Sclerosis: A Systematic Review With Meta-AnalysisBruno Kusznir Vitturi, Maria Cellerino, Daniele Boccia, et al.
Journal of Neurology|September 22, 2022
Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 18, 2018
Brain microstructural injury occurs in patients with RRMS despite 'no evidence of disease activity'Asaff Harel, Dylan Sperling, Maria Petracca, et al.
Scientific Reports|September 25, 2020
Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deteriorationMario Amatruda, Maria Petracca, Maureen Wentling, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 28, 2019
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MSMaria Cellerino, Christian Cordano, Giacomo Boffa, et al.
Pageof 32